A review on the recent applications of synthetic biopolymers in 3D printing for biomedical applications.

3D printing technology is an emerging method that gained extensive attention from researchers worldwide, especially in the health and medical fields. Biopolymers are an emerging class of materials offering excellent properties and flexibility for additive manufacturing. Biopolymers are widely used in biomedical applications in biosensing, immunotherapy, drug delivery, tissue engineering and regeneration, implants, and medical devices. Various biodegradable and non-biodegradable polymeric materials are considered as bio-ink for 3d printing. Here, we offer an extensive literature review on the current applications of synthetic biopolymers in the field of 3D printing. A trend in the publication of biopolymers in the last 10 years are focused on the review by analyzing more than 100 publications. Their application and classification based on biodegradability are discussed. The various studies, along with their practical applications, are elaborated in the subsequent sections for polyethylene, polypropylene, polycaprolactone, polylactide, etc. for biomedical applications. The disadvantages of various biopolymers are discussed, and future perspectives like combating biocompatibility problems using 3D printed biomaterials to build compatible prosthetics are also discussed and the potential application of using resin with the combination of biopolymers to build customized implants, personalized drug delivery systems and organ on a chip technologies are expected to open a new set of chances for the development of healthcare and regenerative medicine in the future.

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.

Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes related to FXS. The early short-term clinical trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials. We evaluated basimglurant, a potent and selective mGluR5 NAM, in a 12-week, double-blind, parallel-group study of 183 adults and adolescents (aged 14-50, mean 23.4 years) with FXS. Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of basimglurant. The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score. All treatment arms showed marked behavioral improvements from baseline to week 12 with less improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total score. Treatment with basimglurant was overall well-tolerated. A higher incidence of adverse events classified as psychiatric disorders were reported in patients treated with basimglurant, including three patients with hallucinations or psychosis. In this phase 2 clinical trial, basimglurant did not demonstrate improvement over placebo. Evaluation of the overall risk-benefit in younger patient populations is an important consideration for the design of potential further investigations of efficacy with this class of medications.

Profound differences in the transcriptome of Campylobacter jejuni grown in two different, widely used, microaerobic atmospheres.

It was noted that quantitative and qualitative differences occurred between the growth of Campylobacter in microaerobic atmospheres provided by a gas replacement jar and that in a modular atmosphere controlled system cabinet, despite the fact that oxygen levels were comparable. Hydrogen was, however, only present in the replacement mixture (3%). Investigations were therefore carried out to examine any accompanying physiological or transcriptional differences. Growth curves and motility studies using Campylobacter jejuni HPC5 showed that cultures growing in the cabinet were impaired, but only in the early stages of growth compared to growth in the jar. However, transcriptome studies highlighted profound changes in the transcript profiles of exponential cultures grown in the cabinet compared to the jar, including genes indicative of oxidative stress. Genes involved in detoxification, synthesis and modification of macromolecules, probable prophage genes and genes associated with inhibition of natural transformation showed relative increases in expression in the cabinet. Conversely, genes that function in energy metabolism, chaperones, heat shock and motility were increased in the jar, which was indicative of balanced growth. This work highlights the need to carefully annotate the different methods of atmosphere generation in the description of experiments in microarray databases; the assessment of these experimental details is crucial to overcome difficulties in comparing transcriptomic studies of campylobacter cultures between different laboratories.